Ardelyx Inc
Company Overview
Ardelyx, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines that target diseases with significant unmet medical needs. The company's primary focus is on developing treatments for gastrointestinal and cardiorenal diseases. Their lead product, IBSRELA® (tenapanor), is approved for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults, and XPHOZAH® (tenapanor), which was recently approved for controlling serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $98.24m | $101.29m | - | $5.28m | 0.00% | 5.21% |
| June 30, 2024 | $73.22m | $91.75m | - | $4.9m | 0.00% | 5.34% |
| March 31, 2024 | $46.02m | $74.76m | - | $4.06m | 0.00% | 5.43% |
Company Impact
Help us evaluate Ardelyx Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.